Skip to main content
SpringerLink
Log in
Book cover

Post-Transplant Lymphoproliferative Disorders pp 105–116Cite as

Prognostic Factors for PTLD

  • Chapter

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Carbone PP, Kaplan HS, Musshoff K. Report of the committee on Hodgkin's disease staging classification. Cancer Res. 1971;31:1860–1

    PubMed  CAS  Google Scholar 

  2. Rosenberg SA. Validity of the Ann Arbor staging classification for the non-Hodgkin's lymphomas. Cancer Treat Rep. 1977;61:1023–7

    PubMed  CAS  Google Scholar 

  3. Anon. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987–94

    Article  Google Scholar 

  4. Bakker NA, van Imhoff GW, et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant. 2005;19(3):327–34

    Article  PubMed  Google Scholar 

  5. Ghobrial IM, Habermann TM, McGregor CG. Differences between early and late posttrans-plant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases. Transplantation. 2005;79(2):244–7

    Article  PubMed  Google Scholar 

  6. Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005;46:191–6

    Article  PubMed  CAS  Google Scholar 

  7. Hourigan MJ, Doecke J, Peter N. Gandhi MK. A new prognosticator for post-transplant lym-phoproliferative disorders after renal transplantation. Br J Haematol. 2008;141(6):904–7

    Article  PubMed  Google Scholar 

  8. Leblond V, Dhedin N, Brunee MF. Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol. 2001;19(3):772–8

    PubMed  CAS  Google Scholar 

  9. Muti G, Cantoni S, Oreste P. Post-transplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica. 2002;87(1):67–77

    PubMed  Google Scholar 

  10. Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplant lym-phoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol. 2007;86(8):599–607

    Article  PubMed  CAS  Google Scholar 

  11. Trofe JT, Buell JF, Beebe TM. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn international transplant tumor registry experience. Am J Transplant. 2005;5(4):775–80

    Article  PubMed  Google Scholar 

  12. Tsai DE, Hardy CL, Tomaszewski JE. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Tranplantation. 2001;71(8):1076–88

    Article  CAS  Google Scholar 

  13. Lucas KG, Filo F, Emanuel DJ. Semiquantitative Epstein-Barr virus polymerase chain reaction analysis of peripheral blood from organ transplant patients and risk for the development of lymphoproliferative disease. Blood. 1998;92(10):3977–8

    PubMed  CAS  Google Scholar 

  14. Webber SA, Naftel DN, Canter CE. Lymphoproliferative disordrers after paediatric heart transplantation: a multi-institutional study. Lancet. 2006;367:233–9

    Article  PubMed  Google Scholar 

  15. Caillard S, Lelong C, Pessione F. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French registry. Am J Transplant. 2006;6:2735–42

    Article  PubMed  CAS  Google Scholar 

  16. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood. 1999;94:2208–16

    PubMed  CAS  Google Scholar 

  17. Micallef IN, Chhanabhai M, Gascoyne RD, et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant. 1998;22:981–7

    Article  PubMed  CAS  Google Scholar 

  18. Benkerrou M, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 1998;92 (9):3137–47

    PubMed  CAS  Google Scholar 

  19. Buell T, Gross M, Hanaway JE Post-transplant lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37(2):954–5

    Article  PubMed  CAS  Google Scholar 

  20. Haldas J, Wang W, Lazarchick J. Post-transplant lymphoproliferative disorders: T-cell lymphoma following cardiac transplant. Leuk lymphoma. 2002;43(2):447–50

    Article  PubMed  Google Scholar 

  21. Lundell R, Elenitoba-Johnson KS, Lim MS. T-cell posttransplant lymphoproliferative disorder occurring in a pediatric solid-organ transplant patient. Am J Surg Pathol. 2004;28(7):967–73

    Article  PubMed  Google Scholar 

  22. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplant lymphoproliferative disorders. J Clin Oncol. 2006;23:7574–82

    Article  Google Scholar 

  23. Paranjothi S, Yusen R, Trulock PE. Lymphoproliferative disease after lung transplantation: comparison of presentation and outcome of early and late cases. J heart lung transplant. 2001;20(10):1054–63

    Article  PubMed  CAS  Google Scholar 

  24. Oton AB, Hong W, Melhem M, et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders: BCL2 as a prognostic marker. J Clin Oncol. 2007;25(18):8073. ASCO Annual Meeting Proceedings, Abstract

    Google Scholar 

  25. Gross TG, Bucuvalas JC, Park JR. Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol. 2005;23:6481–8

    Article  PubMed  CAS  Google Scholar 

  26. Fohrer C, Caillard S, Argyro K, et al. Long-term survival in post-transplant lymphoprolifera-tive disorders with a dose-adjusted ACVBP regimen. Brit J Haem. 2006;134:602–12

    Article  CAS  Google Scholar 

  27. Hayashi RJ, Kraus MD, Patel AL. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23:14–18

    Article  PubMed  CAS  Google Scholar 

  28. Kremers WK, Devarbhavi HC Wiesner RH. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant. 2006; 6:1017–24

    Article  PubMed  CAS  Google Scholar 

  29. Maecker B, Jack T, Zimmerman M. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007;31:4902–8

    Article  Google Scholar 

  30. Lister TA, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: cotswolds meeting. J Clin Oncol. 1989;7:1630–6

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Pennsylvania, Philadelphia, PA, USA

    Tapan Maniar

  2. Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA, USA

    Donald Tsai

Authors
  1. Tapan Maniar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donald Tsai
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pediatric Kidney Transplantation, Shands Hospital at UF, University of Florida College of Medicine Medical Director, Gainesville, Florida, USA

    Vikas R. Dharnidharka (Associate Professor and Chief Fellowship Program Director Division of Pediatric Nephrology) (Associate Professor and Chief Fellowship Program Director Division of Pediatric Nephrology)

  2. Division of Infectious Diseases Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Michael Green (Professor of Pediatrics and Surgery) (Professor of Pediatrics and Surgery)

  3. Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

    Steven A. Webber (Professor of Pediatrics, Chief, Division of Cardiology Co-Director, Heart Center Medical Director, Pediatric Heart and Heart-Lung Transplantation) (Professor of Pediatrics, Chief, Division of Cardiology Co-Director, Heart Center Medical Director, Pediatric Heart and Heart-Lung Transplantation)

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Maniar, T., Tsai, D. (2010). Prognostic Factors for PTLD. In: Dharnidharka, V.R., Green, M., Webber, S.A. (eds) Post-Transplant Lymphoproliferative Disorders. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01653-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01653-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01652-3

  • Online ISBN: 978-3-642-01653-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation